Connor, Clark & Lunn Investment Management (CC&L)
SAGE

Connor, Clark & Lunn Investment Management (CC&L)’s Sage Therapeutics SAGE Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-187,048
Closed -$1.49M – 1665
2025
Q1 		$1.49M Buy
187,048
+17,991
+11% +$132K 0.01% 814
2024
Q4 		$918K Buy
169,057
+103,495
+158% +$633K ﹤0.01% 965
2024
Q3 		$473K Buy
+65,562
New +$600K ﹤0.01% 1112
2023
Q3 		– Sell
-93,329
Closed -$4.39M – 1518
2023
Q2 		$4.39M Sell
93,329
-15,293
-14% -$761K 0.02% 426
2023
Q1 		$4.56M Sell
108,622
-7,043
-6% -$303K 0.02% 388
2022
Q4 		$4.41M Buy
115,665
+56,482
+95% +$2.16M 0.03% 380
2022
Q3 		$2.32M Buy
59,183
+5,540
+10% +$214K 0.02% 467
2022
Q2 		$1.73M Buy
53,643
+11,140
+26% +$373K 0.01% 499
2022
Q1 		$1.41M Sell
42,503
-30,874
-42% -$1.16M 0.01% 591
2021
Q4 		$3.12M Buy
73,377
+19,544
+36% +$818K 0.02% 432
2021
Q3 		$2.38M Buy
+53,833
New +$2.47M 0.01% 489
2021
Q2 		– Sell
-10,596
Closed -$793K – 1088
2021
Q1 		$793K Buy
10,596
+5,904
+126% +$484K ﹤0.01% 727
2020
Q4 		$406K Buy
+4,692
New +$346K ﹤0.01% 749

Other funds holding SAGE

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s SAGE Position: Q2 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Sage Therapeutics (SAGE) in Q2 2025, closing a stake of 187,048 shares — an estimated $1.49M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in SAGE in Q4 2020 and held it in 13 quarters. The position peaked at $4.56M in Q1 2023. 192 funds tracked by Wall St. Rank hold SAGE as of Q2 2025.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Sage Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 187,048 Sage Therapeutics shares in Q2 2025, an estimated $1.49M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Sage Therapeutics in Q4 2020 and held it in 13 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Sage Therapeutics position peaked at $4.56M in Q1 2023.
  • 192 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2025, filed 7 Aug 2025.